Works matching DE "ADALIMUMAB"
Results: 2203
PSORIASIFORM DERMATITIS AFTER DOSE OPTIMIZATION OF TWO DIFFERENT BIOLOGICS IN A PATIENT WITH ULCERATIVE COLITIS: A CASE REPORT.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases.
- Published in:
- Journal of Pharmacy Technology, 2025, v. 41, n. 2, p. 90, doi. 10.1177/87551225241306675
- By:
- Publication type:
- Article
Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment.
- Published in:
- Journal of Clinical Medicine, 2025, v. 14, n. 4, p. 1228, doi. 10.3390/jcm14041228
- By:
- Publication type:
- Article
Effects of Adalimumab, an Anti-tumour Necrosis Factor-Alpha (TNF-α) Antibody, on Obese Diabetic Rats.
- Published in:
- Malaysian Journal of Medical Sciences, 2018, v. 25, n. 4, p. 51, doi. 10.21315/mjms2018.25.4.5
- By:
- Publication type:
- Article
Add or switch to systemics and biologics where topical paediatric hidradenitis suppurativa therapy fails.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 6, p. 211, doi. 10.1007/s40267-024-01076-7
- By:
- Publication type:
- Article
Several approved biologic agents are now available to treat paediatric plaque psoriasis.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 2, p. 72, doi. 10.1007/s40267-022-00896-9
- By:
- Publication type:
- Article
Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects.
- Published in:
- Current Medical Literature: Rheumatology, 2014, v. 33, n. 1, p. 11
- By:
- Publication type:
- Article
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
- Published in:
- Current Medical Literature: Rheumatology, 2014, v. 33, n. 1, p. 10
- By:
- Publication type:
- Article
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled Phase 4 trial.
- Published in:
- 2013
- By:
- Publication type:
- Opinion
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a Phase IIIb, multinational, prospective, randomized study.
- Published in:
- 2013
- By:
- Publication type:
- Opinion
Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.
- Published in:
- Current Medical Literature: Rheumatology, 2013, v. 32, n. 1, p. 30
- By:
- Publication type:
- Article
Spondyloarthritis.
- Published in:
- Current Medical Literature: Rheumatology, 2012, v. 31, n. 4, p. 129
- Publication type:
- Article
Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs.
- Published in:
- Clinical Rheumatology, 2024, v. 43, n. 7, p. 2287, doi. 10.1007/s10067-024-07012-4
- By:
- Publication type:
- Article
Evaluation of inflammatory biomarkers and the ratio of hemoglobin-red cell distribution width in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha inhibitors.
- Published in:
- Clinical Rheumatology, 2024, v. 43, n. 6, p. 1815, doi. 10.1007/s10067-024-06963-y
- By:
- Publication type:
- Article
Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
- Published in:
- Clinical Rheumatology, 2023, v. 42, n. 6, p. 1593, doi. 10.1007/s10067-023-06529-4
- By:
- Publication type:
- Article
Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial.
- Published in:
- Clinical Rheumatology, 2022, v. 41, n. 10, p. 3005, doi. 10.1007/s10067-022-06199-8
- By:
- Publication type:
- Article
Clinical efficacy and safety of adalimumab versus etanercept in patients with ankylosing spondylitis and total spinal ankylosis in Croatia: a multicentre 12-month follow-up study.
- Published in:
- Clinical Rheumatology, 2022, v. 41, n. 8, p. 2417, doi. 10.1007/s10067-022-06177-0
- By:
- Publication type:
- Article
Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study.
- Published in:
- Clinical Rheumatology, 2022, v. 41, n. 3, p. 731, doi. 10.1007/s10067-021-05943-w
- By:
- Publication type:
- Article
Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis.
- Published in:
- Clinical Rheumatology, 2021, v. 40, n. 11, p. 4369, doi. 10.1007/s10067-021-05933-y
- By:
- Publication type:
- Article
Magnetic resonance imaging in ankylosing spondylitis: reduction of active sacroiliitis and hip arthritis during treatment with an adalimumab biosimilar.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
- Published in:
- Clinical Rheumatology, 2021, v. 40, n. 1, p. 85, doi. 10.1007/s10067-020-05199-w
- By:
- Publication type:
- Article
Comparison of signal detection of tumour necrosis factor-α inhibitors using the Korea Adverse Events Reporting System Database, 2005–2016.
- Published in:
- Clinical Rheumatology, 2020, v. 39, n. 2, p. 347, doi. 10.1007/s10067-019-04802-z
- By:
- Publication type:
- Article
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis.
- Published in:
- Clinical Rheumatology, 2019, v. 38, n. 12, p. 3381, doi. 10.1007/s10067-019-04679-y
- By:
- Publication type:
- Article
Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review.
- Published in:
- Clinical Rheumatology, 2019, v. 38, n. 2, p. 591, doi. 10.1007/s10067-018-4328-3
- By:
- Publication type:
- Article
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis.
- Published in:
- Clinical Rheumatology, 2019, v. 38, n. 1, p. 63, doi. 10.1007/s10067-018-4069-3
- By:
- Publication type:
- Article
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies.
- Published in:
- Clinical Rheumatology, 2018, v. 37, n. 10, p. 2805, doi. 10.1007/s10067-018-4133-z
- By:
- Publication type:
- Article
Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab.
- Published in:
- Clinical Rheumatology, 2018, v. 37, n. 6, p. 1715, doi. 10.1007/s10067-018-4092-4
- By:
- Publication type:
- Article
Postoperative adalimumab maintenance therapy for Japanese patients with Crohn’s disease: a single-center, single-arm phase II trial (CCOG-1107 study).
- Published in:
- Surgery Today, 2018, v. 48, n. 6, p. 609, doi. 10.1007/s00595-018-1634-y
- By:
- Publication type:
- Article
Bone tissue reaction, setting time, solubility, and pH of root repair materials.
- Published in:
- Clinical Oral Investigations, 2019, v. 23, n. 3, p. 1359, doi. 10.1007/s00784-018-2564-1
- By:
- Publication type:
- Article
Impact of adalimumab on erectile dysfunction, sperm parameters and hormonal profile in male psoriasis patients: a six-month observational study.
- Published in:
- Archives of Dermatological Research, 2024, v. 317, n. 1, p. 1, doi. 10.1007/s00403-024-03520-0
- By:
- Publication type:
- Article
Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Anti-TNFα Treatment in Children and Adolescents With Combined Inflammatory Bowel Disease and Autoimmune Liver Disease.
- Published in:
- 2018
- By:
- Publication type:
- journal article
P066. Potential utility of therapeutic drug monitoring of adalimumab in predicting short-term endoscopic and histologic remission in pediatric Crohn's disease patients.
- Published in:
- Journal of Pediatric Gastroenterology & Nutrition, 2017, v. 65, p. S51
- By:
- Publication type:
- Article
P065 Efficacy of first line top-down adalimumab therapy.
- Published in:
- Journal of Pediatric Gastroenterology & Nutrition, 2017, v. 65, p. S51
- By:
- Publication type:
- Article
P064. Evaluation of Adalimumab Effectiveness in Anti-Tumor Necrosis Factor-Naïve Pediatric Patients with Crohn's Disease in Clinical Practice.
- Published in:
- Journal of Pediatric Gastroenterology & Nutrition, 2017, v. 65, p. S50
- By:
- Publication type:
- Article
EP37. Efficacy and safety of adalimumab after infliximab failure in pediatric ulcerative colitis: a real-life experience from the sigenp-IBD registry.
- Published in:
- Journal of Pediatric Gastroenterology & Nutrition, 2017, v. 65, p. S23
- By:
- Publication type:
- Article
Efficacy and Safety of Adalimumab After Infliximab Failure in Pediatric Crohn Disease.
- Published in:
- Journal of Pediatric Gastroenterology & Nutrition, 2015, v. 60, n. 6, p. 744, doi. 10.1097/MPG.0000000000000713
- By:
- Publication type:
- Article
Well-Defined and Reliable Clinical Outcome Assessments for Pediatric Crohn Disease: A Critical Need for Drug Development.
- Published in:
- Journal of Pediatric Gastroenterology & Nutrition, 2015, v. 60, n. 6, p. 729, doi. 10.1097/MPG.0000000000000793
- By:
- Publication type:
- Article
Adalimumab Treatment in a Case of Treatment-Resistant Acne Conglobata.
- Published in:
- European Journal of Therapeutics, 2024, v. 30, n. 4, p. 562, doi. 10.58600/eurjther2220
- By:
- Publication type:
- Article
Interrupted course of antitumor necrosis factor alpha therapy versus combined nonsteroidal anti-inflammatory drug therapy and physiotherapy in patients with ankylosing spondylitis: A comparative study.
- Published in:
- Journal of Medicine in Scientific Research, 2021, v. 4, n. 3, p. 210, doi. 10.4103/JMISR.JMISR_106_20
- By:
- Publication type:
- Article
First-line Treatment With Vedolizumab Linked to Fewer Hospitalizations, Surgeries in IBD.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 11, p. 16
- By:
- Publication type:
- Article
Higher Adalimumab Concentration Linked to Complete Healing in Perianal Fistulizing Crohn's.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 8, p. 39
- By:
- Publication type:
- Article
FDA Approves High-Concentration, Citrate-Free Form of Interchangeable Biosimilar Cyltezo.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 6, p. 30
- By:
- Publication type:
- Article
Benefit of Biosimilar Switching ‘Less Apparent’ to GIs, Patients vs. Third-Party Payers.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 4, p. 7
- By:
- Publication type:
- Article
Triple Combination Therapy ‘Superior to Monotherapy,’ Improves Remission in Crohn’s.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 38
- Publication type:
- Article
Multiple sclerosis associated with adalimumab use in ankylosing spondylitis.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Impact of Treatment with Methotrexate and TNF Alpha Inhibitors on Insulin Resistance in Patients with Psoriasis.
- Published in:
- Turkiye Klinikleri Journal of Dermatology, 2020, v. 30, n. 2, p. 35, doi. 10.5336/dermato.2020-74503
- By:
- Publication type:
- Article
Biological Drug Use in Patients with Psoriasis: Our Clinical Experiences.
- Published in:
- Turkiye Klinikleri Journal of Dermatology, 2018, v. 28, n. 3, p. 81, doi. 10.5336/dermato.2018-62612
- By:
- Publication type:
- Article
Immunological Changes in Peripheral Blood of Ankylosing Spondylitis Patients during Anti-TNF- Therapy and Their Correlations with Treatment Outcomes.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept.
- Published in:
- BioMed Research International, 2021, p. 1, doi. 10.1155/2021/4450162
- By:
- Publication type:
- Article